All In Biotech

Drug Trial Radar · NCT07448597

Progesterone Preeclampsia

Progesterone Supplementation for the Prevention of Preeclampsia

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 642 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

642

Planned (sponsor's estimate)

Start

Aug 13, 2026

Primary completion

Aug 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Medical University of South CarolinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.

Conditions

  • Preeclampsia
  • Hypertensive Disorder of Pregnancy

Interventions

  • Progesterone supplementationDrug

    Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of preeclampsiaTime frame: Antenatally and up to 6 weeks postpartum

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.